title: Ocriplasmin: nonsurgical option for VMA and macular hole, but with potential barriers to practical use.
authors.affiliation: Retina Consultants of Michigan, Southfield, MI 48034, USA. obermike@gmail.com
authors.forename: Michael D
authors.initials: MD
authors.lastname: Ober
authors.forename: Seenu M
authors.initials: SM
authors.lastname: Hariprasad
mesh_terms: D002986:Clinical Trials as Topic; D017277:Drug Approval; D005341:Fibrinolysin / Q000009:adverse effects / Q000627:therapeutic use*; D005343:Fibrinolytic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D010446:Peptide Fragments / Q000009:adverse effects / Q000627:therapeutic use*; D012164:Retinal Diseases / Q000188:drug therapy*; D012167:Retinal Perforations / Q000188:drug therapy*; D000267:Tissue Adhesions / Q000188:drug therapy*; D014481:United States; D014486:United States Food and Drug Administration; D014822:Vitreous Body / Q000187:drug effects*
chemical_list: D005343:Fibrinolytic Agents; D010446:Peptide Fragments; C054561:microplasmin; D005341:Fibrinolysin